Strategic Plan Objective Detail
Interagency Autism Coordinating Committee (IACC) logo
Office of Autism Research Coordination (OARC) logo

Question 3: Objective 3  

$713,227.00
Fiscal Year: 2008

Yellow dot: Objective has some degree of funding, but less than the recommended amount.3.3 Within the highest priority categories of exposures for ASD, identify and standardize at least three measures for identifying markers of environmental exposure in biospecimens by 2011. IACC Recommended Budget: $3,500,000 over 3 years.

Download 2008 Question 3: Objective 3 projects (EXCEL)
Note: Initial Sort is by Principal Investigator. Sorting by other columns is available by clicking on the desired column header.
Project Title Principal Investigator Institution
Genetics of autism intermediate phenotypes Coon, Hilary University of Utah
Core C: Analytical core Hammock, Bruce University of California, Davis
Clinical trial: Greater NY Autism Research Center / Citalopram treatment in children Bregman, Joel Feinstein Institute For Medical Research
Biomarkers of response to environmental stressors: Measurement of environmental exposures to metals and chemical toxicants Birnbaum, Eva Caldera Pharmaceuticals, Inc.

Objective Cumulative Funding Table

IACC Strategic Plan Objectives 2008 2009 2010 2011 2012 Total
Within the highest-priority categories of exposures for ASD, identify and standardize at least three measures for identifying markers of environmental exposure in biospecimens by 2011.

IACC Recommended Budget: $3,500,000 over 3 years
3.3
$713,227
4 projects

3.S.B
$0
0 projects

3.S.B
$0
0 projects

3.S.B
$0
0 projects

3.S.B
$100,000
1 project

$813,227
3.S.B. Funding: The recommended budget was not met; the funding allocated to projects specific to this objective falls far short of the recommendation.

Progress: There has been progress on the understanding of exposures, but more work needs to be done to apply this directly to autism research. Progress has made through methodological advances embedded in epidemiological studies funded by NIEHS, but those projects are not captured by the Portfolio Analysis because they are not specific to autism.

Remaining Gaps, Needs, and Opportunities: The primary obstacle to completion of this objective has been availability of funding to identify and validate exposure markers. There is a need for biomarkers of exposure; exposomics should be a priority area for future research.